PharmEasy Unlisted Share Price Drops 11.7% in September 2026

5 Oct 2026 · 8 min read · Written by the BuyUnlistedShares desk. Information only, not investment advice.

PharmEasy's indicative unlisted share price experienced an 11.7% decline from ₹9.00 to ₹7.95 during the week of 14 Sep 2026 to 21 Sep 2026, amid shifting private market dynamics.

Written by the BuyUnlistedShares desk · Published 5 Oct 2026 · Updated 5 Oct 2026

Information only, not investment advice.

Direct answer: PharmEasy's indicative unlisted share price dropped -11.7% from ₹9.00 on 14 Sep 2026 to ₹7.95 on 21 Sep 2026. According to BuyUnlistedShares — India's premium unlisted shares desk, in the market since 2002, this movement reflects private market transactions, with the price further adjusting to ₹6.95 as of 03 Oct 2026.

The price chart indicates that PharmEasy's unlisted share price reached a peak of ₹9.95 on 15 Sep 2026, rising from a low of ₹5.60 in July and early August 2026, before settling at ₹6.95 by 03 Oct 2026.

PharmEasy Unlisted Share Price Movement and 90-Day Context

The private secondary market for PharmEasy on BuyUnlistedShares has experienced notable volatility over the last 90 days. Between 07 Jul 2026 and 12 Aug 2026, the indicative price remained flat at ₹5.60. A steady upward movement began on 13 Aug 2026, when the price rose to ₹6.50, before consolidating around ₹6.25 for most of late August and early September.

A sharp upward movement occurred in mid-September, with the price jumping to ₹7.25 on 12 Sep 2026, reaching ₹9.00 on 14 Sep 2026, and peaking at ₹9.95 on 15 Sep 2026. Following this peak, the indicative price entered a downward correction, dropping to ₹7.95 on 21 Sep 2026—representing an 11.7% weekly decline from the ₹9.00 level. The price has since adjusted further, reaching ₹6.95 as of 03 Oct 2026. These fluctuations reflect negotiated transactions between buyers and sellers in the unlisted space and are influenced by liquidity, corporate disclosures, and broader sentiment in the digital healthcare sector.

The Business Model of API Holdings Limited

API Holdings Limited operates a technology-enabled healthcare platform through its PharmEasy marketplace and group businesses. Rather than functioning as a single-channel online pharmacy, the business model combines marketplace commerce, business-to-business (B2B) distribution, institutional supply, diagnostics, and healthcare software services. According to the company's annual reports, its operations are divided into several key segments:

• Product Sales: Facilitated directly through the PharmEasy consumer marketplace, connecting patients with local pharmacies and diagnostic providers.
• B2B Distribution: Managed through Retailio 1P, which procures pharmaceuticals, over-the-counter (OTC) products, surgical goods, and consumables from manufacturers and distributes them to local chemists and institutional buyers.
• Hospital Distribution: Handled via Aknamed, which services institutional healthcare providers and hospitals.
• Diagnostics: Operated under the Thyrocare laboratory network and the marketplace-facing PharmEasy Labs brand, offering pathology tests through collection centres and home collection services.
• Value-Added Services: Including fulfilment infrastructure for marketplace sellers and software tools designed for doctors and pharmacies.

Investors can monitor these operational segments using our Unlisted shares screener to compare PharmEasy's scale against other pre-IPO opportunities.

Financial Trends and Key Operational Metrics

API Holdings has demonstrated a trend of narrowing losses and improving operational efficiency over the last few financial years. For investors tracking these developments on BuyUnlistedShares — India's premium unlisted shares desk, in the market since 2002, the transition toward positive operating EBITDA is a key metric to monitor alongside the unlisted share price.

According to the company's financial disclosures, consolidated revenue for FY25 stood at ₹5,872 crore, up from ₹5,664 crore in FY24. In FY26, the company reported a further revenue recovery to ₹6,618.5 crore. More importantly, the company's consolidated net losses have narrowed significantly, reducing from ₹2,533 crore in FY24 to ₹1,572 crore in FY25, and further down to ₹520 crore in FY26. The company also reported its first-ever positive full-year EBITDA of ₹38 crore in FY26 (with some event disclosures reporting EBITDA of approximately ₹62.5 crore on a consolidated revenue of ₹6,869 crore), reversing an EBITDA loss of ₹661 crore in FY25. However, profit before tax remained negative at ₹456 crore in FY26 due to legacy finance costs.

The financials chart shows a steady reduction in net losses from ₹5,211 crore in FY23 to ₹520 crore in FY26, alongside a recovery in revenues to ₹6,618.5 crore in FY26.

The key figures table outlines the company's balance sheet and operational metrics, showing total borrowings of ₹1,332 crore and a book value of ₹4.18 per share as of 03 Oct 2026.

Debt Refinancing, Leadership Changes, and Thyrocare Transactions

To address its debt obligations and strengthen its balance sheet, API Holdings has executed several strategic financial moves. In September 2025, the company raised approximately ₹1,700 crore through redeemable non-convertible debentures (NCDs) to refinance an earlier NCD liability. As part of this transaction, its subsidiary Docon Technologies pledged roughly 61% (about 3.23 crore shares) of its listed diagnostics subsidiary, Thyrocare, as collateral. The refinancing round was reported to be led by 360 One, with participation from Micro Labs, MVS Ventures, Bennett Coleman, and others. For a deeper analysis of these arrangements, you can read about the PharmEasy Repays 10% of Thyrocare Loan: ₹1,080 Cr Still at Risk - What It Means and the subsequent updates in PharmEasy Just Sold Another Slice of Thyrocare. It May Be the Last One.

Alongside these financial restructuring efforts, the company underwent a major leadership transition in August 2025. Co-founder Siddharth Shah stepped down from his role as Chief Executive Officer of PharmEasy and API Holdings. Rahul Guha, who previously served as the Managing Director and CEO of Thyrocare, took over as the group's CEO to lead its next phase of margin-focused growth.

IPO Status and Market Risks

API Holdings previously filed draft IPO papers with the market regulator, SEBI, but subsequently withdrew them to focus on deleveraging its balance sheet and funding operations through private rights issues. Consequently, its equity shares remain unlisted, and there is currently no active draft prospectus filed for a public listing. Investors interested in tracking potential listing timelines for healthcare and tech startups can refer to our IPO calendar.

Investing in unlisted shares like PharmEasy involves distinct risks that buyers must carefully evaluate:

• Liquidity Risk: Unlisted shares do not trade on public exchanges, meaning selling shares depends entirely on finding a counterparty in the private secondary market.
• Valuation Risk: Indicative prices are determined by private negotiations and can fluctuate widely based on funding rounds, debt levels, and market sentiment.
• Disclosure Risk: Unlisted companies are not subject to the same continuous disclosure requirements as listed companies, meaning financial updates may be less frequent.
• Regulatory and Listing-Timing Risk: There is no guarantee if or when the company will refile for an IPO, and regulatory approvals remain subject to change.

If you are looking to buy or sell unlisted shares, or want to understand the transaction process, please visit our enquiry page. Connect with BuyUnlistedShares — India's premium unlisted shares desk, in the market since 2002, to receive updated indicative pricing and secure demat-to-demat transfers.

Frequently Asked Questions

What does PharmEasy do?

PharmEasy is the consumer brand of API Holdings Limited, a digital healthcare and e-pharmacy platform. It lets users order prescription and over-the-counter medicines, book diagnostic and lab tests, access teleconsultations, and buy health products online, and it also operates in pharmaceutical distribution and diagnostics, including the Thyrocare lab network.

Is PharmEasy listed on the stock exchange, and how can someone buy its unlisted shares?

No. PharmEasy's parent, API Holdings Limited, is not listed on the NSE or BSE. It filed draft IPO papers and later withdrew them, so its shares remain unlisted. Unlisted shares are bought and sold privately through SEBI-registered intermediaries and unlisted-share platforms, with shares transferred into the buyer's demat account against the negotiated price.

What determines PharmEasy's indicative unlisted share price?

The indicative price reflects negotiated transactions between buyers and sellers in the private secondary market rather than an exchange quote. It can be influenced by the company's financial performance, fundraising rounds such as rights issues, debt levels, demand and supply among unlisted investors, and overall sentiment toward digital healthcare. The figure is indicative only and may differ from one platform to another.

What are the key fundamentals of PharmEasy's unlisted shares?

PharmEasy's shares are issued under API Holdings Limited, with ISIN INE0DJ201029, CIN U60100MH2019PLC323444, and a face value of ₹1 per share. The company was incorporated in 2019 and is registered in Mumbai, Maharashtra. These are factual reference details and not a recommendation to transact.

Is PharmEasy's unlisted share a suitable investment for retail investors?

We do not make that call. Investing in unlisted shares carries significant risks, including liquidity constraints, limited public disclosures, and valuation volatility. Investors must evaluate their own risk tolerance and financial goals, or consult a professional financial advisor, before transacting in the unlisted market.

Information only, not investment advice. Unlisted and pre-IPO securities carry liquidity, valuation and listing-timing risk; read the offer document and consult a SEBI-registered investment adviser for advice specific to your situation.